熱門資訊> 正文
Neoleukin Therapeutics报告财年业绩
2025-03-25 04:24
- Neoleukin Therapeutics press release (NASDAQ:NGNE): FY Revenue of $0.93M beats by $0.16M.
- Net income for the twelve months ended December 31, 2023 included a one-time $16.4 million bargain purchase gain related to the reverse merger.
- Cash, cash equivalents and marketable securities as of December 31, 2024, were $312.4 million and are expected to provide runway into the second half of 2027, which would allow for the completion of enrollment of a future registrational trial for NGN-401 for Rett syndrome, CMC scale-up to support NGN-401 registrational activities and further development of Neurogene’s EXACT™ gene therapy pipeline.
More on Neoleukin Therapeutics
- Neurogene: Potential To Target Root Cause Of Rett Syndrome With NGN-401
- Seeking Alpha’s Quant Rating on Neoleukin Therapeutics
- Historical earnings data for Neoleukin Therapeutics
- Financial information for Neoleukin Therapeutics
推薦文章
港股周報丨三家外賣平臺被約談！「瘋狂星期六」或不再瘋狂；花旗呼籲增持中國互聯網、科技及消費板塊
美股機會日報 | 特朗普放大招！9萬億養老金即將殺入加密市場；美聯儲主席候選人支持7月降息
一周財經日曆 | 特斯拉、谷歌財報重磅來襲！維立志博將於下周五登陸港交所
一圖看懂 | 港股上半年IPO募資額登頂全球！中籤就賺一萬港幣的「大肉籤」你參與了嗎？
黃仁勛年內三度訪華！H20重返中國市場，釋放了什麼信號？
創新葯行情徹底爆發！維立志博-B打新半日孖展超購130倍，凍資近150億港元
新股申購 | 維立志博-B入場費3535.30港元！引入騰訊、易方達等基石投資者
7月財報預告丨迎關税考驗！特斯拉、臺積電放榜在即，美股能否守住漲勢？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
